Ex-Bausch + Lomb CEO takes helm at Forest Labs

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

Ex-Bausch + Lomb CEO takes helm at Forest Labs

Forest Laboratories ($FRX) tapped Brent Saunders, once the CEO at Bausch + Lomb, to replace the retiring Howard Solomon. Saunders has been on Forest's board since 2011 and will take over the CEO position in October. The company emphasized the length of the search process for Solomon's successor--activist Carl Icahn butted heads with the former chief in two proxy fights, a situation Forest could mitigate with Saunders' appointment. More from FiercePharma | Forest release

Forest Laboratories
Brent Saunders will be the new CEO.

Cold Spring Harbor Laboratory
Teri Willey will be vice president of business development and technology transfer.

Biotech

Cold Spring Harbor Laboratory appointed Teri Willey to be the company's new vice president of business development and technology transfer. She held a similar position at Mt. Sinai Medical Center and co-founded Arch Development Partners, a venture group. Item | Release

Assurex Health appointed former Procter & Gamble executive Gina Coleman Drosos to be the company's president leading its personalized medicine growth. Release

Raymond Keane joined Intarcia Therapeutics as the company's vice president, general counsel and chief legal officer. Release

Endo Health Solutions ($ENDP) appointed Suketu Upadhyay to be the company's new chief financial officer. Upadhyay formerly served as the principal accounting officer and interim chief financial officer at Becton Dickinson ($BDX). Release

ImmusanT named Ferdinand E. Massari as its chief medical officer and senior vice president of development. Release

Sanomedics International Holdings brought on Mark Miklos to be general manager and director of business development for its newly acquired company Prime Time Medical. Release

Adheron Therapeutics appointed Hari Kumar to be the company's CEO and Robert Baltera to be its board's executive chairman. Release

Biocept appointed Michael Nall as the company's CEO. Nall was most recently the general manager of North American sales and marketing at GE Healthcare's Clarient. Release

As part of a restructuring Celtaxsys, Dr. Michael Hanley has retired from his role as CEO and chairman. Dr. H. Daniel Perez, a member of the Celtaxsys Board and former CEO of Berlex Biosciences and Presidio Pharmaceuticals, is serving as chairman. Release

Xenon Pharmaceuticals has appointed Ian Mortimer as chief financial officer. He is currently executive vice president and chief financial officer at Tekmira Pharmaceuticals. Release

Regeneron Pharmaceuticals ($REGN) has appointed Robert Landry as senior vice president of finance. Landry will also assume the position of chief financial officer of on Oct. 1. Landry most recently served as senior vice president and treasurer of Pfizer ($PFE). Release

Edge Therapeutics has elected Dr. Robert Spiegel to the company's board of directors. Spiegel spent over 25 years at Schering-Plough and retired in 2009 as chief medical officer and senior vice president of the Schering-Plough Research Institute. Release

Celladon Corporation, a 2012 Fierce 15 company, has appointed Gregg Alton and Graham Cooper to its board of directors. Release

Dr. David Hangauer will join Kinex Pharmaceuticals as chief science officer. Most recently, Hangauer was an associate professor of chemistry at the University of Buffalo. Release

Barbara Lopez Kunz has taken up the post of global chief executive at DIA. She was previously president of the Global Health and Life Sciences business at Battelle. Release

Pharma

Carolyn F. Sidor will serve as Kolltan Pharmaceuticals' chief medical officer. Release

Baxter ($BAX) bumped Todd Young up to the roles of treasurer and corporate officer. Young formerly served as the company's president of international finance. Release

Cardioxyl Pharmaceuticals appointed Shi Yin Foo as the company's chief medical officer. Release

Drug Delivery

Catalent Pharma Solutions brought on David Heyens to be the company's president of its Asia Pacific arm, Catalent Softgel Technologies. Release

CRO

Thomas D'Ambra will retire as president and CEO of Albany Molecular Research to be replaced by William Marth, currently the company's non-executive chairman. Release

> Dr. Geeta Sharma has joined Agilux Laboratories as senior director of pharmacology. Most recently, Sharma was senior director of pharmacology at Forma Therapeutics at the company's Singapore location. Release

Theorem Clinical Research has promoted veteran U.K. researcher Phil Lake to head its biopharmaceutical franchise in respiratory. Lake joined Theorem in 2012 as senior director of project management. Release

Manufacturing

Goodwin Biotechnology has appointed SooYoung Lee as chief operating officer. Lee has held positions at SAIC Frederick, Schering-Plough Research Institute, Wyeth Lederle Vaccines, AppTec, Neose Technologies and Genencor. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.